AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 51 min read$EQ

Connelly Stephen sold $724K of EQ

Connelly Stephen (President and CSO) sold 230,975 shares of Equillium, Inc. (EQ) at an average of $3.13 ($2.94–$3.16, $0.72M total) across 2 trades over 2026-06-04 to 2026-06-05.

Original reporting
SEC EDGAR · Connelly Stephen
Published Jun 5, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EQ
Bearish
medium confidence
Mentioned
$EQ
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQBearishLow
01

Why it matters

The disclosed sale may prompt short‑term selling pressure on EQ as investors react to the insider's reduction of stake.

02

Market read

A modest insider sell by a senior executive, likely to cause slight downward pressure on EQ.

03

What to watch

No 10b5‑1 plan was used, indicating a discretionary decision that may reflect personal liquidity needs.

Relevance 5/10Novelty 4/10Timing: after-hours filing on 2026-06-05

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$EQBearishMedium confidence
Context

President and CSO Connelly Stephen sold 230,975 shares for $723,830, reducing his stake to 762,025 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A senior officer sold a sizable block (~30% of his holdings) at market prices, which traders often interpret as a bearish signal.

Market effects

Sector

Minimal impact on the broader biotech sector; only a single insider transaction.

Regional

US market only; no regional ripple.

Global

Low; the filing is company‑specific.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • company
    Equillium, Inc.

    Biotech firm listed on NYSE under ticker EQ.

  • person
    Connelly Stephen

    President and Chief Scientific Officer of Equillium.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EQ insider trading history →

Related articles

MAY 29
$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP

dailypolitical.com7 min
SEP 29
$COURMedAI 8/10

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $11.4M of COUR (indirect holdings)

Pale Fire Capital SE purchased 2,332,742 indirectly-held shares of Coursera, Inc. (COUR) at an average of $4.87 ($4.61–$5.06, $11.36M total) across 2 trades over 2026-09-25 to 2026-09-29. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min